Nanotechnology approaches in chronic wound healing

Comprehensive invited review

Barbara Blanco-Fernandez, a Oscar Castaño, b,a,c,d Miguel Ángel Mateos-Timoneda, c,a,f ≠
Elisabeth Engel, f,c,a Soledad Pérez-Amodio, c,a,f

a Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10–12, 08028 Barcelona, Spain
b Serra Hunter Fellow. Electronics and Biomedical Engineering, Universitat de Barcelona (UB), Martí i Franquès 1, 08028 Barcelona, Spain
c CIBER en Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain
d Bioelectronics Unit and Nanobioengineering Lab., Institute for Nanoscience and Nanotechnology of the University of Barcelona (IN2UB), Joan XXIII S/N, 08028 Barcelona, Spain
f Materials Science and Metallurgical Engineering, Polytechnic University of Catalonia (UPC), Eduard Maristany 16, 08019 Barcelona, Spain
≠ Present address: Bioengineering Institute of Technology, Universitat Internacional de Catalunya C/Josep Trueta, S/N, 08195 Sant Cugat del Valles, Barcelona, Spain.

Running head: Nanotechnology in chronic wound healing

Corresponding author:

Soledad Perez-Amodio, Ph.D.
Biomaterials for Regenerative Therapies
Institute for Bioengineering of Catalonia
Baldiri i Reixac 15-21. 08028 Barcelona, Spain
0034934020214
sperez@ibecbarcelona.eu

Word count (excluding abstract, references, and figure legends): 7479

Manuscript keywords: Diabetes, chronic, wound healing, nanoparticles, nanofibers, liposomes
Abstract

Significance

The incidence of chronic wound is increasing due to our aging population and the augment of people afflicting with diabetes. With the extended knowledge on the biological mechanisms underlying these diseases, there is a novel influx of medical technologies into the conventional wound care market.

Recent Advances

Several nanotechnologies have been developed demonstrating unique characteristics that address specific problems related to wound repair mechanisms. In this review, we focus on the most recently developed nanotechnology-based therapeutic agents and evaluate the efficacy of each treatment in in vivo diabetic models of chronic wound healing.

Critical Issues

Despite the development of potential biomaterials and nanotechnology-based applications for wound healing, this scientific knowledge is not translated into an increase of commercially available wound healing products containing nanomaterials.

Future Directions

Further studies are critical to provide insights into how scientific evidences from nanotechnology-based therapies can be applied in the clinical setting.
1. **SCOPE AND SIGNIFICANCE**

This review highlights new nanoplatforms created for the treatment of chronic wounds, specifically diabetic wounds. We briefly introduce the despaired wound healing of chronic wounds and drugs/biomolecules that are being used, and particularly discuss the use of nanoparticles, nanofibers and liposomes in the treatment of diabetic wounds, emphasizing their mechanisms of action.

2. **TRANSLATIONAL RELEVANCE**

Nanotechnology driven therapeutics can influence a specific biochemical event within the impaired healing process, being able to change one or more wound-healing phases.

This offers unique opportunities compared to dressing-based the conventional wound care products.

A major advantage of these nanoplatforms is their adaptability and tunability. For instance, nanotherapeutics can be used in controlled and sustained released of the active ingredient over a period of days or weeks, while conventional delivery systems such as dressings films or gels can sustain the release of the therapeutic agent over 1 to 2 days.

**CLINICAL RELEVANCE**

Chronic wounds have an important economic impact in developed countries, and it is expected to increase as the population ages. Current therapies cannot fully address the impaired healing, provoking wound complications like infections and poorly wound closure. Thus, new biomolecules and therapies that promote wound healing, prevent wound infections or inflammation, among others, are needed. Several nanotechnological approaches with multiple functions and different mechanisms have proved their potential in wound animal models, and could be the next generation of wound nanotherapies.
4. BACKGROUND

4.1. Chronic wounds

Chronic wounds exhibit a disturbed repair process, provoking that wounds would not heal within three months. Among them, non-healing pressure ulcers (NHPUs), venous ulcers (VUs), and diabetic foot ulcers (DFUs) are the most common ones. VUs are caused by dysfunctional blood valves or obstructed veins, mainly in legs. On the other hand, NHPUs are skin and underlying tissue injuries caused by prolonged skin pressure in people confined to bed or with limited mobility for long time periods. DFUs often start from several diabetes complications such as foot deformity, peripheral arterial diseases and peripheral neuropathy. Diabetic neuropathy is the result of nerve damage caused by uncontrolled glucose blood levels, and it reduces the skin sensitivity. Foot deformation leads to the formation of keratosis and callus, resulting in wound aggravation and even gangrene. Diabetic patients have also alterations in the capillary system (thickening of basement membrane, reduced capillary size, etc). Over time, alterations in the glucose levels contribute to vasoconstriction and plasma hypercoagulability, developing occlusive arterial disease, ischemia and ulcer formation (peripheral arterial disease). Non-healing ulcers have a considerable impact for patients and their families. These types of wounds cause loss of function, morbidity, severe pain, infections, hospitalization and in some cases amputations. Chronic wounds mostly arise associated to population ageing, obesity and diabetes, increasing the health costs. This disease is often not regarded as a high priority compared to other conditions because it is not considered to be life-threatening. Chronic wounds prevail as a silent epidemic affecting the wellbeing of over 40 million people in the world.

Most of the common features of chronic wounds include an extended inflammatory phase, existence of persistent infections, formation of bacterial biofilms as well as higher levels of proteases and ROS species. Furthermore, dermal and/or epidermal cells residing in chronic wounds, fail to respond to reparative stimuli. These cells present phenotypic abnormalities such as lower expression of growth factor (GF) receptors as well as lower mitogenic potential, preventing their response to external environmental cues. The higher levels of proteases in chronic wounds promote the destruction of ECM, GF
receptors and GF like platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF) and transforming growth factor-beta (TGF-β).  

The higher ROS levels observed in chronic wounds also stimulates the ECM destruction and cell damage. All these cellular abnormalities do not allow the formation of granulation tissue and extracellular matrix (ECM) deposition, resulting in the formation of nonhealing wounds. Another feature of chronic wounds is impaired angiogenesis. Angiogenesis is a physiological process required for wound healing. In normal wound healing this process depends on the balance between the growth and proliferation of vessels and their maturation and quiescence. In diabetic patients, this balance is disrupted. Endothelial cells exposed to elevated glucose levels have been reported to become senescent leading to integrity loss and eventually apoptosis. This decreased angiogenesis is also due to macrophage deficit present in these wounds, since these cells produce high levels of vascular endothelial growth factor (VEGF) and other pro-angiogenic mediators.

4.2. Current treatments of chronic wounds

Current treatment of chronic wounds depends on the wound etiology. In all cases, an adequate wound cleaning and debridement, a control of possible infections and the use of wound dressings is needed. NHPUs treatments include dressings that accelerate the wound healing and relieve the tissue pressure. However, DFUs and VU focus on dressing that maintains the moist environment conducive to wound healing and on compression. Specifically, compression leg bandages are used in VUs to improve the vein circulation. Conventional dressings, such as gauze or gauze-woven cotton composite dressings, provide wound protection from bacterial contamination and allow gaseous/fluid exchange. They are used as secondary dressings to cover complex dressings or for the treatment of superficial and non-infected wounds. Specifically, compression leg bandages are used in VUs to improve the vein circulation.

These materials are characterized for their easy use and low cost. However, disadvantages like frequent changes needs, lack of control of moisture levels and adherence to the
wound bed have restricted their usage in wound management.\textsuperscript{10} Nowadays, new synthetic dressings, capable of providing suitable a moist environment, are available. These dressings are semi-occlusive or occlusive. They can be in the form of film, foam, hydrogel, or hydrocolloids. They are fabricated using a variety of synthetic materials like poly(vinyl alcohol (PVA), poly(lactide-co-glycolide) (PLGA), polyurethanes (PU), polyethylene glycol (PEG), polycaprolactone (PCL), nylon or silicone. Among them, hydrogels are seeing as promising biomaterial suitable for wound dressings due to their high-water content.

Hydrogels can maintain the moist environment at the wound interface whilst absorbing excessive exudate, allow gaseous exchange, act as barrier to microorganisms, and do not adhere to the wound bed.

Generally, hydrogels are a made of natural polymers such as collagen and chitosan and synthetic polymers (PVA, PEG, etc) to achieve optimal mechanical properties.

4.3. New therapeutics in the treatment of chronic wounds

Within the last decade, significant improvements in the development of new therapies have been done, like integrating additives such as antimicrobial molecules, immunomodulatory cytokines, GF, miRNA or exosomes.\textsuperscript{11} Advanced devices releasing antimicrobial agents, such as iodine or silver, are effective in reducing the bacterial load in the wound bed.

Some commercially available examples in Europe and USA are ActisorbTM Silver220 and Iodosorb\textsuperscript{®}. Antimicrobial peptides are able to control both inflammation and bacterial infection, acting as wound-healing peptides. These properties are highly desired in novel topical formulations for treatment of chronic wounds.\textsuperscript{12}

Regarding GFs, several studies have demonstrated that their use improve all aspects of tissue repair in animal models.\textsuperscript{13} The success of topically administered GFs in in chronic wounds is limited. Due to their short in vivo half-life, low absorption rate through the outermost skin later around the wound as well as rapid elimination by exudation before reaching the wound bed, might limit the efficacy of GFs topical application. Current strategies using GF may not provide the needed time for GFs in the wound area to interact with the target cells, due to their high degradation rate.\textsuperscript{14}
Conventional medications containing GFs need to be applied in high doses and/or being repeatedly administrated over a long period, leading to important side effects and increasing the cost of the therapy. GFs delivery systems that improve their stability in the wound area and control their release provide more effective and secure treatment alternatives. Presently, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and epidermal growth factor (EGF) are widely studied for their application in GF-mediated wound repair.\textsuperscript{15}

Several approved products that include GFs are supplied as medications for external use in the form of solutions, gels, creams, and ointments. Clinical trials of topically administered GF have reported contradictory evidence for therapeutic outcomes.\textsuperscript{16} There are some commercially available formulations containing growth factors like recombinant human PDGF (rhPDGF, Regranex\textsuperscript{®} Gel), recombinant human basic fibroblast growth factor FGF (bFGF, Fiblast\textsuperscript{®} Spray) and recombinant human EGF (Heberprot-\textsuperscript{P}, Regen-D\textsuperscript{™} 150, and Easyef\textsuperscript{®}). Regranex\textsuperscript{®} Gel is an aqueous-based sodium carboxymethylcellulose gel containing 0.01\% becaplermin (rhPDGF) approved for topical use by the Food and Drug Administration (FDA). Fiblast\textsuperscript{®} Spray is a recombinant human basic fibroblast growth factor FGF (bFGF) product commercialized in Japan.

Another characteristic of biological dressings is their ability to interact with cells or matrix proteins in the wound bed to promote healing. The ECM is a combination of structural and functional proteins. These proteins are produced by skin cells and arranged into specific patterns, which are responsive for the physiologic and biomechanical requirements of skin. The three-dimensional (3D) ultrastructure of ECM also provides a scaffold that promotes cell organization, proliferation and differentiation during the process of wound healing.

Today, commercially available acellular ECM scaffolds include porcine-derived small intestinal submucosa (e.g. Oasis\textsuperscript{®} wound matrix), porcine urinary bladder matrix (e.g. MatriStem UBMTM), bovine dermis (e.g. PriMatrix\textsuperscript{®} and MatriDerm\textsuperscript{®}), equine pericardium (Matrix Patch\textsuperscript{™}). Devitalized ECM scaffolds are also commercially available (EpiFix\textsuperscript{®}).
These acellular biological products function as temporary substrates into which cells can migrate and proliferate in a well-organized and controlled fashion. In this way, they promote granulation tissue formation and tissue regeneration.

Since the use of ECM-based scaffolds alone seems to be limited for chronic wound care due to an absence of interaction with cells and tissues, autologous cellular elements have been included in these scaffolds.¹⁷

These living skin equivalents address the damaged ECM by adding a collagen matrix and also provide immune-privileged living cells that proliferate and actively synthesize GFs, cytokines, and ECM components, creating an optimal wound healing environment.⁶

Some examples of skin equivalent substitutes commercially available are: Apligraf®, Dermagraft®. and AlloDerm™. Apligraf® is an FDA product containing an epidermal keratinocyte layer and a dermal layer of fibroblast-seeded collagen. Dermagraft®, also FDA approved, is formed by a polymeric scaffold seeded with neonatal allogeneic fibroblasts. These cell-based biological dressings offer an enormous potential in the field of chronic wound management, acting in several ways to improve wound healing.¹⁸

MicroRNAs (miRNA) are highly conserved endogenous small non-coding RNA molecules participating in various biological processes including diabetic wound healing. miRNAs regulate post-transcriptional gene expression by binding to their target messenger RNAs (mRNAs), leading to mRNA degradation or translation suppression.¹⁹ miRNAs are known to be altered in chronic wounds indicating that these molecules are also implicated in impaired angiogenesis.²⁰ In vivo studies using diabetic mice reported that miRNAs were differently expressed in skin cells and that their levels of expression changed during the wound healing process.²¹

Other studies have demonstrated the in vivo upregulation of miR-129 and -335 enhanced wound closure through the inhibition of Sp1-mediated matrix metalloproteinases -9 (MMP-9) expression in a diabetic wound model.²²
RNA delivery techniques have improved in the last years, leading to the creation of functionalized wound dressings carrying stable miRNA or anti-miRNA molecules for skin wound healing applications.23

This has led to an increase in available anti-miRNA-based strategies parallel to that of the functional miRNA transfection approach. For example, light-inducible synthetic antimiR-92a and Locked Nucleic Acid-antimiR-26a show progress made in this respect.24

In another study, synthetic microRNA-92a inhibitor25 reported increased angiogenesis and wound healing in different animal models such as diabetic mice and normal pig.25

Although their effect in chronic wounds has not been reported yet, exosomal miRNAs obtained from umbilical cord mesenchymal stem cells, human amniotic epithelial cells and human umbilical cord blood plasma have demonstrated to be useful in wound healing.26

5. DISCUSSION OF FINDINGS AND RELEVANT LITERATURE

5.1. Needs of new delivery systems in chronic wound: Nanotechnology

Current therapies to treat chronic wounds are intended to cover the wound, protect against bacterial infection, remove dead tissue, provide moistening and absorb excess of fluid.27 Nanotechnology platforms, due to their characteristics have demonstrated new promises and benefits in the field. Recent progress in nanotechnology have open new areas in the field of drug delivery applications, allowing the delivery of biomolecules like DNA/RNA or GFs; that can be applied in chronic wound healing. Their small size and physic-chemical properties allow the intracellular delivery of these biomolecules or drugs, protects these agents from degradation and enhance the drug penetration into the wound. All together allows the topical administration and increases the half-life of these agents, lowering the number of applications and costs. In addition, the encapsulation of drugs and biomolecules inside nanocarriers enable different drug release profiles, that can match the wound healing requirements. In the next sections, we will review the NPs, nanofibers and self-assembled nanocarriers used for the treatment of chronic wounds (Fig. 1), specifically that have proved positive results in wound healing in diabetic animal models.
5.2. Nanoparticles

Nanoparticles with a diameter of 1-100 nm, are highly explored in the field of biomedicine and tissue engineering. In wound healing, they can be subdivided in two main categories: NPs with intrinsic properties positive for wound healing and, NPs as drug delivery systems. Their main advantages are the controlled and sustained release, increase drug half-life and bioavailability.

5.2.1. NPs with intrinsic activity for wound healing

When developing strategies to address the healing of chronic wounds, technologies not using drugs or biologics are attractive to lower product fabrication costs and reduced time to market. Metallic NPs made of silver, copper oxide, gold, iron oxide, zinc oxide (ZnO), aluminum oxide, titanium dioxide, and gallium have proved their antibacterial properties.\(^{28, 29, 30, 31, 32}\) Its activity is caused by the production of reactive oxygen species (ROS)\(^{33}\) and the interaction with RNA, DNA and enzymes (inhibitory), all together provoke bacteria death (Fig. 2). Other materials with intrinsic activity are cerium, bioactive glass (BG), carbon-based and bearing nitric oxide NPs.

Although these NPs have useful properties, therapies that use metals are limited because excessive levels of metals, especially heavy metals, may damage human cells. Table 1 summarizes the NPs formulations that have been tested in diabetic wound healing in animal models and have proved its activity in wound healing and as antibacterial agents. Amongst heavy metals, silver has been used as an antimicrobial agent due of its relatively low toxicity to human.\(^{34}\) Recently, in response to issues concerning antibiotic resistance, topical application of medicals containing silver have become popular.\(^{35}\)

Silver NPs (AgNPs) are probably the most used NPs in wound healing due to its antimicrobial, anti-inflammatory and wound healing properties (inducing myofibroblasts differentiation from fibroblasts and stimulating keratinocyte proliferation/relocation).\(^{36}\) Moreover, no bacterial resistance and toxicity was observed. Nevertheless, silver ions release from the NPs can lead to toxicity,\(^{37}\) through oxidative
stress by the generation of ROS. This problem strongly depends on different NP features such as size, shape, concentration, agglomeration or aggregation. Thus, its inclusion in other formulations to control ions release is needed to reduce its cytotoxicity. AgNPs have been incorporated in gels, like hyaluronic, PEG-chitosan, polyacrylic acid and foams, among others, that had proved their efficiency in diabetic wound healing and in the reduction in bacteria count. For example, Shin et al. prepared hydrogels made of maleic acid-grafted dextran and thiolated chitosan impregnated with AgNPs. This hydrogel behaves as antifouling materials, improving the performance of AgNPs. They provided a slow Ag⁺ release, that promoted the wound healing due to its antibacterial activity, inhibition of inflammation, and modulation of the immune response. Zhao et al., fabricated conductive hydrogels mimicking skin made of polydopamine decorated with AgNPs, polyaniline and PVA with potential as epidermal sensors and wounds healing agents. The resulting hydrogels had adequate self-healing properties, repeatable adhesiveness, antibacterial activity and promoted angiogenesis and collagen deposition. The impregnation of cellulose nanocrystals matrix with AgNO₃ NPs has also shown interesting results in diabetic wound healing. A reduction in inflammation and an increase in collagen deposition, re-epithelialization and angiogenesis was observed, promoting wound healing. In terms of clinical trials, however, there is not enough evidences to establish whether AgNPs- containing dressings or topical agents promote wound healing or prevent wound infection. For DFUs, as well, no randomized trials or controlled clinical trials exist that analyse their clinical effectiveness, although new devices are developed that suggest that more clinical trials are needed. Gold NPs (AuNPs) have inherent antibacterial activity and promote the process of wound healing through hemostasis and inflammatory phases.
AuNPs have recently been used by various research groups for their wound-healing applications. AuNPs have been combined with biomolecules like antioxidants\textsuperscript{52} to enhance the wound healing activity of the formulation. Martinez et al. fabricated a nanocomposite made of Au NPs functionalized with chitosan and calreticulin,\textsuperscript{53} a calcium-binding protein of the endoplasmic reticulum that has shown wound healing activity.\textsuperscript{54}

When administered into diabetic mouse wounds, improved healing was observed compared to untreated mice. Randeira et al. made AuNPs conjugates with a spherical nucleic acid of ganglioside-monosialic acid 3 synthase (GM3S) dispersed in Aquaphor (Fig. 3). This enzyme is overexpressed in diabetic mice and impedes wound healing. Treated wounds in diabetic mice decreased the local enzyme expression and fully healed in 12 days, with an increase in granulation tissue formation and vascularity (Fig. 3).\textsuperscript{55}

Copper ions (Cu\textsuperscript{2+}) also promote wound healing in diabetic mice\textsuperscript{56,57,58} due to its pro-angiogenic properties.\textsuperscript{59} Cu\textsuperscript{2+} stabilize the expression of hypoxia-inducible factor and promote the secretion of VEGF, mimicking hypoxia, that plays a role in cell recruitment, cell differentiation and blood vessel formation.\textsuperscript{60}

In addition, Cu\textsuperscript{2+} has antimicrobial activity.\textsuperscript{61} However, multiple applications are necessary,\textsuperscript{62} provoking copper toxicity. Slower ions release can reduce its toxicity.

Metal–organic frameworks (MOFs) are a type of crystalline porous coordination polymers composed by inorganic metal ions and organic ligands that interact to form clusters with tunable release rates, being also efficient in diabetic wound healing.\textsuperscript{63,64} Xiao et al. prepared MOFs modified with folic acid that released slowly Cu\textsuperscript{2+} and improved the wound closure by inducing angiogenesis, collagen synthesis and re-epithelialization.\textsuperscript{63} Copper-based MOFs however, might be unstable in physiological protein containing solutions, making difficult their direct use in wound healing.\textsuperscript{63}

ZnO NPs also exhibit activity in wound healing.\textsuperscript{65} So far, zinc promotes re-epithelialization, pro-angiogenesis and it is anti-inflammatory.\textsuperscript{66} Other metallic NPs like graphene oxide,\textsuperscript{67} iron oxides or titanium have been also included in wound healing alternatives with positive results.\textsuperscript{68} However, further studies need to be performed to ensure their efficacy in diabetic wound healing. Cerium oxide NPs (CeONPs) have been proven to have antioxidant
and pro-angiogenic activity, enhancing diabetic wound healing,\textsuperscript{68,69} being even effective in the treatment of DFUs.\textsuperscript{70} BGs have also been reported to be successful in wound healing applications due to their high biocompatibility and positive biological responses of their ionic products.\textsuperscript{71}

Several reports indicate that BG NPs can efficiently enhance diabetic wound healing. Lin and coworkers reported an accelerated wound healing in diabetic rats probably due to an increase in angiogenesis related factors such as VEGF and FGF-2.\textsuperscript{72}

Silicon (Si) ions have also been used for the treatment of diabetic wounds. Jiang et al. prepared a spaced-oriented scaffold for Si ions release. The scaffolds were coated with silicon-doped amorphous calcium phosphate NPs coating its surface to promote angiogenesis.\textsuperscript{73} The Si ions released promoted wound healing by enhancing angiogenesis, collagen deposition and re-epithelialization of the diabetic wound. Porous Si NPs loaded with Flightless I neutralizing antibodies showed a significant improvement in healing compared to controls and the antibody alone in diabetic wounds.\textsuperscript{74}

Nitric Oxide (NO) is a potent anti-biofilm in wound healing and it has been proved that diabetic wounds have a low NO level in the wound bed.\textsuperscript{75}

NO has been formulated in NPs to improve wound healing in diabetic animal models.\textsuperscript{76} NO-releasing NPs prepared by doping PLGA NPs with polyethylenimine/diazeniudiolate have been reported to accelerate healing of methicillin-resistant \textit{Staphylococcus aureus} biofilm-infected wounds in diabetic mice together with biofilm clearance and reduced bacterial count.\textsuperscript{77}

Overall, we must highlight that mostly bioactivity and mechanism proposed in the literature are related to the ion species rather than the metal or oxide. That means that features that affect degradability and dissolution such as particle size, crystallinity and solubility should be strongly controlled.

5.2.2. NPs as drug delivery systems

NPs can also be used in wound healing as encapsulation platforms (Table 2). Polymers like polyesters, polysaccharides, peptides and lipids can be used for their preparation. PLGA
can release lactate into the wound bed to promote neovascularization and wound healing.\textsuperscript{78} PLGA has been used to encapsulate a variety of molecules, like insulin,\textsuperscript{79} ferulic acid,\textsuperscript{80} and GFs,\textsuperscript{78, 81, 82} showing accelerated wound healing in diabetic rodent models. For example, wounds treated with NPs encapsulating VEGF have an increase in collagen deposition, re-epithelialization and angiogenesis in diabetic wounds.\textsuperscript{78} When compared with free VEGF, wounds required only 19 days to be completely closed in the case of VEGF encapsulated in the PLGA NPs compared with the 28 days for free GF.\textsuperscript{78}

Lipid NPs (LNPs) are generally prepared with physiological lipids or lipid molecules in processes that do not require any potentially toxic organic solvents. Generally, for wound healing applications, LNPs are loaded with specific siRNAs. Topical application of LNPs formulated with an ionizable and degradable lipid and a siRNA specific for tumor necrosis factor alpha (TNF\(\alpha\)) have shown a decreased TNF\(\alpha\) mRNA expression in the wound bed by 40–55\% in diabetic mice compared to untreated wounds.\textsuperscript{83} Another example of lipid NPs application in chronic wounds are lecithin-based NPs. Topical application of these NPs complexed with deferoxamine in a model of wound healing in diabetic rats, showed an increased wound closure along with an improved collagen deposition and neovascularization when compared with free deferoxamine. This suggests the NPs encapsulating the therapeutic have a better healing outcome than the free therapeutic.\textsuperscript{84}

NPs made of peptides have also shown their utility in the field of wound healing. Elastin-like proteins (ELP) -based fusion proteins, by forming NPs, have been shown to protect biomolecules from proteolysis, and can act as “drug depots” that supply the biomolecules over an extended period. Recently, self-assembling elastin-like peptides GF chimeric NPs have been used to treat chronic wounds. These NPs of ELP and Keratinocyte Growth Factor (KGF)\textsuperscript{85} or ELP and stromal cell-derived factor I (SDF)\textsuperscript{86,87} were applied to excisional wounds on the back of diabetic mice. These treatments showed accelerated wound closure and increased vascularization as compared to free GF, ELP alone, or vehicle (Fig. 4). Other peptide, such as the cationic antimicrobial peptide protamine has been reported to be suitable for the development of treatments for chronic wounds. Wang and co-workers developed protamine NPs and hyaluran oligosaccharide loaded in alginate hydrogels. Using a diabetic mouse-skin defect model, these authors demonstrated that this
composite reduced bacterial-induced chronic inflammation at the wound site and accelerated the wound-healing process by promoting angiogenesis.\textsuperscript{88}

### 5.3. Nanofibers

Nanofibers are filaments with diameters within the nanoscale. They are usually produced by the electrospinning technique due to its low cost and simplicity. This technique uses a high electric force between a needle point capillary tip and a collector, to spin the polymeric solutions, and obtain fiber meshes. Nanofibers meshes are a promising tool in the field of chronic wounds as they can partially reproduce the ECM due to its organization and random alignment. Indeed, its high surface area-to-volume ratio and tunable porous morphology can promote the wound homeostasis as well as allows the gas/nutrients interchange.\textsuperscript{89}

Moreover, nanofiber meshes should also provide moisture to avoid the wound dehydration and bacteria contamination. They can also encapsulate biological molecules, drugs or nanocarriers encapsulating those, which consequently allows their topical administration with the subsequent advantages (lower dose and less side effects). On the other hand, nanofiber meshes has also being tested as artificial skin. When mesenchymal stem cells (MSC) are used they can differentiate into endothelial cells or release GFs to trigger the wound healing process.\textsuperscript{90}

Nanofibers can be categorized depending on their composition (natural polymers, artificial polymers, polymer blends). Table 3 describes the strategies followed for diabetic wound healing.

#### 5.3.1. Natural polymers

Natural polymers offer an excellent biocompatibility and biodegradability, low antigenicity, and even, some of them have innate properties for wound healing (antibacterial and hemostatic activity). Among them, polysaccharides and proteins are often used for nanofiber preparation. The main limitation for its use is its innate variability and the poor mechanical properties, normally requiring their combination with synthetic polymers.
5.3.1.1. Polysaccharides

Polysaccharides like chitosan, alginate and hyaluronic acid have emerged as good candidates in wound dressings due to their innate properties, similarities with the skin ECM and abundance. However, its use in chronic wounds is still limited. The fabrication of polysaccharide nanofibers through electrospinning is challenging, due to the critical chain entanglement concentration (CEC), \(^{91}\) that it might be too high (hyaluronic) provoking high or insufficient viscosity (alginate).

Alginate is one of the most used biomaterials for the developing of wound dressings, \(^{92}\) being even some commercially available options (Tegagen\textsuperscript{TM}). It is generally combined with synthetic polymers like polyethylene oxide (PEO) to be electrospun. \(^{93}\) Its use in chronic wounds has not been tested yet.

Chitosan has innate antibacterial and hemostatic activity. \(^{94}\) However, its chemical characteristics (hydrogen bonds, amino groups) reduces its chains flexibility, limiting the fabrication of nanofibers. \(^{94}\) Chitosan has been electrospun using strong acids to break chemical interactions or combining it with other polymers, like poly(ethylene oxide) (PEO), PVA or PCL. \(^{95}\) Xie and co-workers created a scaffold made of chitosan and PEO, loaded with VEGF and NPs encapsulating PDGF-BB. The scaffold had antibacterial activity due to chitosan and released VEGF in the early stage to promote blood vessel formation. \(^{95}\)

In addition, NPs were able to slow the release of PDGF-BB over time promoting the formation of new blood vessels and cell proliferation during the wound healing process.

Chitosan/PVA nanofibers have a good wound healing profile by itself, \(^{96}\) and they were also combined with other therapeutics like desferrioxamine. \(^{97}\) These nanofibers sustained desferrioxamine release for 3 days, and were able to recruit cells to promote angiogenesis in chronic wounds through the hypoxia-inducible factor 1-alpha (HIF-1a) expression and other pro-angiogenic GFs.

ZnO was also encapsulated into chitosan/PVA fibers to implement its antimicrobial and antioxidant activities. \(^{92}\) Chitosan/gelatin nanofibers containing BG were also tested in chronic wounds treatment, proving their antibacterial activity and healing properties. \(^{93}\)
Hyaluronic acid is a natural constituent of the ECM, having a relevant physiological role in inflammation and wound healing. Its molecular weight (MW) determines its activity; MWs greater than 15KDa renders polymers recognized by the CD44 receptor, which induces fibroblasts migration and proliferation and cell growth, and are beneficial for wound healing. Hyaluronic electrospinning is challenging due to its high viscosity at the CEC, forcing the combination with other materials. Nevertheless, some authors have reported the fabrication of nanofibers when it is dissolved in strong acids or bases and dimethylformamide. Collagen/hyaluronic nanofibers encapsulating angiogenic GFs (VEGF, PDGF) and GF-loaded gelatin NPs (EGF and bFGF) were assayed as skin substitutes. The nanofibrous membrane possessed similar mechanical properties to human skin and allowed a faster wound regeneration than the control. The formulation was able to release EGF and bFGF in the early stage of the wound (to promote epithelialization and angiogenesis), and PDGF and VEGF in the late stage (to aid vasculature maturation), promoting enhanced wound healing.

Abdel-Mohsen and co-workers prepared hyaluronan nanofibers containing AgNPs. The nanofibers had antibacterial activity against gram negative bacteria and higher wound repair efficacy when compared to controls, proving its efficacy in wound and chronic ulcers. Cellulose derivatives are also used for the preparation of nanofibers through electrospinning. Grip et al. used hydroxypropyl methylcellulose (HPMC) combined with PEO to form nanofibers encapsulating beta-glucan. Nanofibers were prepared by the Nanospider™ technology. When used in vivo in diabetic mice, they showed an improved wound healing capacity.

5.3.1.2. Proteins

The most used proteins for the fabrication of nanofibers for wound healing are silk fibroin (SF), gelatin, and collagen. Insects and arachnids naturally produce SF, which is a very common protein applied in the electrospinning process to produce strong fibers due to its mechanical properties. These nanofibers have demonstrated to accelerate wound dressing
Chouhan et al. showed that SF nanofibers loaded with antibiotic and EGF had a faster wound healing in diabetic rabbits than other commercially available bandages. These authors also fabricated fibers combining SF with PVA and encapsulating EGF together with an antimicrobial peptide. They observed a remarkably faster healing, progress of the granulation tissue formation, angiogenesis and re-epithelialization of the wounds in diabetic rabbits.

Li et al. prepared nanofiber dressing of SF encapsulating microparticles loaded with insulin. Insulin stimulates keratinocyte and endothelial cells proliferation and migration, promoting wound re-epithelialization and vascularization. These authors observed that the dressing improved the wound healing in diabetic rats due to a sustained release of the insulin during the wound healing progress.

Chouhan and coworkers developed nanofibrous meshes of SF coated with 2 classes of recombinant silk fusion proteins from arachnids: FN-4RepCT (contains fibronectin-derived binding motifs) and Lac-4RepCT (includes a cationic antibacterial peptide) (Fig. 5). When mats were coated with both spider silk proteins, they had a faster wound healing, improved granulation, angiogenesis, collagen deposition and re-epithelialization than the uncoated or one single coat in diabetic wounds. SF scaffolds were also used as skin substitutes, by seeding human adipose-MSCs on them. Interestingly, when the scaffolds were decellularized they were almost as effective as the seeded scaffolds in the treatment of diabetic wounds.

Gelatin is a polyaminoacid obtained by the partial acid or alkaline hydrolysis of natural collagen. It has been widely applied in the area of biomaterials for tissue engineering because of its hemostatic activity, high number of RGD sequences to promote cell adhesion, low antigenicity and easy chemical modification.

Jalaja et al. were able to produce gelatin nanofibers using water solvents by then increasing its water stability crosslinking them with oxidized sucrose, reducing the toxicity associated to other cross-linkers like glutaraldehyde. Aduba et al. electrospun gelatin and arabinoxylan encapsulating silver sulfadiazine, obtaining trifunctional fibers due to its...
antioxidant and antimicrobial activities and similarities with the ECM. However, its instability in water forced to crosslink the fibers, reducing its mechanical properties.\textsuperscript{109}

Gelatin nanofibers encapsulating AgNPs and PDGF-BB, showed a better antibacterial activity, promotion of angiogenesis, re-epithelialization, collagen deposition, and granulation tissue formation in diabetic wounds than the gelatin scaffold (Fig. 6).\textsuperscript{110} PCL was also used for electrospinning gelatin. Lv et al. prepared gelatin/PCL nanofibers encapsulating silicate-based bioceramic particles with a sustained release of Si ions. In vivo, an enhanced angiogenesis, collagen deposition, re-epithelialization and reduction of inflammation was observed.\textsuperscript{111}

Collagen is the main constituent in the ECM, skin and connective tissues and its role in ECM regeneration has been demonstrated. Collagen has been combined with other materials for fabricating dressings by electrospinning. Sun et al. prepared nanofibers of collagen I and PCL with different patterns: mimicking the collagen fibrils pattern in vivo (crossed), random and aligned (Fig. 7). In vitro, fibroblasts responded differently in each nanofiber configuration, having differences in the wound healing related gene expression. Moreover, diabetic rats treated with crossed nanofibers had a faster healing, increased angiogenesis and lower inflammation compared to the other nanofiber architectures.\textsuperscript{112}

Gao et al. also fabricated Collagen 1/PCL nanofibers encapsulating an inhibitor of the prolyl hydroxylases: dimethyloxalylglycine, which is able to avoid HIF-1-alpha degradation.

These fibers were produced by co-axial electrospinning, having a a drug/polymer core and a polymer shell, showing sustained biomolecule release for two weeks and a stabilization of HIF-1a in vivo.

The nanofibers improved wound healing in diabetic rats.\textsuperscript{113} They also prepared similar nanofibers encapsulating a BGs NPs instead. These new nanofibers mimicking the bone ECM improved angiogenesis, granulation tissue formation, ECM remodeling and epidermis differentiation.\textsuperscript{114}
Lee et al. encapsulated recombinant human PDGF in collagen/PLGA nanofibers to test its suitability in chronic wound healing, and they also observed a faster closure rate of the wounds, combined with a higher re-epithelialization and collagen I deposition. When Glucophage is loaded in collagen/PLGA nanofibers, a downregulation of MMP-9 is observed in murine diabetic models, promoting faster healing.

Synthetic polymers have a more defined molecular structure and a better solubility in organic solvents than natural materials, easing its formulation in nanofibers. In addition, most of them, have better mechanical properties than natural polymers.

5.3.2.1. Polyesters

Polyesters are the most used materials for nanofiber formation, owing to their tunable biodegradability, their innate biocompatibility and their approval by the FDA. For example, poly(lactide) (PLA) fibers embedding mesoporous silica NPs loaded with a pro-angiogenic drug (dimethylaminoethylglycine) enhanced new blood vessel formation re-epithelialization and collagen deposition, as well as a decrease in inflammation in a diabetic wound model.

Curcumin-encapsulated PCL nanofibers had also proved its benefits as antioxidants and anti-inflammation in wound healing in diabetic mice. When combining PCL with the curcumin and gum tragacanth, the nanofibers were active against bacteria. MSC seeded scaffolds improved the wound closure rates and it enhanced granulation tissue formation, re-epithelization and collagenous synthesis and even sweat glands and hair follicles formation.

Bixin-encapsulated in PCL nanofibers also proved its efficacy in reducing scar formation and accelerating the wound healing process in diabetic models. PCL nanofibers encapsulating GFs have been also synthetized and tested in chronic wound healing. Choi et al. prepared PCL/ PCL-PEG copolymers blends for electrospinning, making nanofibers with a core of bFGF, that afterwards were chemically modified in their surface with EGF. Animal studies showed that the double encapsulation with a biphasic release profiles, rendered a higher collagen accumulation and keratin cement formation, which implemented the wound closure and reduce the scar formation.

PLGA nanofibers have also a great potential in the development of new wound dressings for chronic wound healing. Molecules like metformin or recombinant human PDGF have
been encapsulated in the fiber meshes, showing a remarkably wound healing. PLGA has also been combined with cellulose nanocrystals or aloe vera to form nanofibers. \textsuperscript{123,124} Neurotensin encapsulated PLGA/cellulose nanocrystals induced a faster healing than controls, with a decrease in inflammatory cytokines and a higher epidermal/dermal regeneration.\textsuperscript{123} PLGA/aloe vera nanofibers encapsulating rhEGF had antimicrobial activity and a faster wound closure and re-epithelization.\textsuperscript{124}

5.3.2.2. Hydrophilic polymers

Hydrophilic polymers like PEG or PVA have also been studied in wound healing due to their hydrophilicity that allows moisture of the wounds and their similarities with the ECM. PVA has been combined with curdlan and silver nitrate to fabricate nanofiber meshes effective against gram positive and gran negative bacteria. The \textit{in vivo} results showed an anti-inflammatory activity and a faster wound healing.\textsuperscript{125} Yang et al. tested whether the incorporation of a GF\textsuperscript{126} into PLGA-PEG copolymers fibers with a core-shell structure could be beneficial in chronic healing. They found out that the scaffolds had a higher neo-vascularization, faster wound closure, better re-epithelization and regeneration of skin appendages.\textsuperscript{127}

5.3.2.3. Self-assembled peptides

Milder fabrication methods for the encapsulation of biomolecules have also been tested to avoid degradation problems of the encapsulated molecules. Self-assembled peptides like the Ac-RADARADARADARADARADA-CN\textsubscript{2} (RADA16) form 3D nanofibers when deposited into wounds and can be used as skin bioequivalents. Schneider and co-workers prepared RAD16 nanofibers encapsulating EGF that increased wound closure rate by 5-fold compared to controls in an \textit{in vitro} human skin equivalent wound healing model.\textsuperscript{128} Balaji et al. proved that the use of angiogenic injectable peptide nanofibers (ACN–RARADARADARADARADA–CN\textsubscript{2}) in diabetic wounds, promoted the angiogenesis and wound closure and reduced the inflammation.\textsuperscript{129} Multidomain peptide nanofibers were also checked in chronic wounds, and they showed an accelerated wound healing rate, high vascularization, granulation, and hair follicle regeneration\textsuperscript{130}
Nanofibers made of heparin-mimic amphiphilic peptides also accelerated wound healing in diabetic-induced and diabetic mice. Treated diabetic mice showed an accelerated wound closure, better re-epithelialization, induction of angiogenesis, and high levels of VEGF during time. TNF-α were elevated only at early stages proving a transition from inflammation to proliferative phases. Pro-inflammatory cytokines were elevated only at early stages proving a transition from inflammation to proliferative phases.

4.4. Liposomes and other self-assembled structures

Liposomes are promising topical drug delivery systems, because they allow the reduction of the drug dosage and it increases the transdermal absorption when compared with traditional emulsions and ointments. Liposomes are sphere-shaped vesicles having one or more lipid bilayers. Liposomes can be classified accordingly to their size (from nm to mm), number of bilayers or the method of fabrication. They are generally prepared from phospholipids and cholesterol.

They can encapsulate hydrophilic (in the internal aqueous compartments) and hydrophobic (in the bilayer) molecules in their structure, making them very suitable for drug delivery to have a slower and constant release of the drug. Liposomal formulations used in the treatment of diabetic rodent wounds are shown in table 4.

Cationic liposomes can work as gene delivery systems by forming complexes with the negative charged nucleic acids. They are made of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). The encapsulation of gens protects them from degradation, increasing the circulation half-life. Moreover, the overall positive charge of the liposome enhances its endocytosis due to interactions with the cell membrane. They can be administered topically or by intradermic/subcutaneous injections. Rabbani et al. prepared cationic liposomes and a peptide-based ternary complexes to increase the transfection of Keap1 siRNA. This molecule can activate antioxidant mechanisms, proving tissue regeneration. They observed that wounds regenerate faster in murine diabetic model.

Li et al. encapsulated miR-132-loaded liposomes in pluronic F127 gels and applied them to diabetic mice on human ex vivo skin wounds. The gels were administered intradermal in the edges of the diabetic wounds, resulting in an accelerated wound healing closure, repressed the inflammation and increased proliferation of keratinocytes.
Moreover, in human *ex vivo* skin wounds, a faster reepithelization of the wounds was observed. They can also encapsulate genes encoding GFs. Bhattacharyya et al. encapsulated the gene encoding for PDGF into liposomes, and with only one subcutaneous administration, wounds were healed with higher degree of epithelization, keratinization, collagen deposition and blood vessel formation compared to controls (Fig. 8).

Chronic wounds are more likely to develop wound infections, especially with multi-drug resistance microorganisms. Thus, new approaches like the phage therapy are appearing. Chhibber et al. encapsulated bacteriophages into cationic liposomes to resolve *Staphylococcus aureus*-infected diabetic mice wounds. Liposomes-treated mice evidenced an accelerated wound closure and healing than the free phages, proving that the reduction of clearance can increase the activity of the phages.

Insulin-loaded liposomes included into a chitosan hydrogel demonstrated its efficacy in chronic wounds in patients, reducing the erythema and the time of wound duration. Wang et al. tried the liposomes using a model of diabetic rabbit with ischemic tissue. They topically administered adenosine triphosphate (ATP)-liposomes in the wounds and observed a faster wound closure than the control.

The encapsulation of GF into liposomes increases its stability and prolongs its release as it protects it against degradation in the wound site. Choi et al. prepared cationic liposomes encapsulating EGF, insulin-like growth factor-1 (IGF-1) and PDGF-A. All the GFs were combined with a low-molecular-weight protamine, complexed with hyaluronic acid and then encapsulated in cationic liposomes made of hydrogenated phosphatidylcholine, cholesterol and DOTAP. Liposomes were able to increase the wound healing ratio, and showed re-epithelialization and dermal tissue remodeling in diabetic mice ulcers because of the combination of GFs and hyaluronic acid and a sustained release of them. SDF-1, known to enhance angiogenesis in ischemic tissues, was encapsulated into liposomes, and then included in decellularized dermis scaffolds. A higher cell proliferation in the dermis was observed, which resulted in faster wound closure and increased granulation.

Another approach followed for the increase of the activity of GFs was developed by Das et al. They studied the delivery of syndecan-4 (a proteoglycan that works as co-receptor of many GFs) into liposomes in combination with PDGF-BB, all embedded in an alginate
dressing. They observed an increase in wound closure rate, angiogenesis and a reduced inflammation.

Micelles are self-assembled structures made of polymers or surfactants that have a hydrophobic and hydrophilic part. They have sizes on the range of 10-100 nm and can encapsulate hydrophobic molecules in its core. Nevertheless, micelles were also poorly explored in wound healing field. Only few authors have reported the use of PLA–PEG, PEG-PCL-PEG or pluronic micelles for encapsulation of drugs like curcumin. Nanogels and nanoemulsions have also been poorly explored in the field of wound healing.

4.5. Future perspectives

The appearance of new biomolecules active in wound healing, like GFs or nucleic acids, shows the necessity of designing new formulations to protect them from degradation and to deliver them at specific rates. The emergence of nanotechnology, especially the fabrication and characterization of nanoparticulate systems, has increased the number of available interventions for healing of chronic wounds.

The new chronic wounds nanotherapeutics are multifunctional platforms that promotes wound healing with minimal scar formation, avoids/treats bacteria contamination and can even release the active biomolecules encapsulated at specific rates that matches wound healing necessities. In addition, they need to be highly biocompatible and encapsulate high amounts of the biomolecule. It is also required that they are easy to apply into the wound, which means, for NPs and self-assembling carriers, to be included in another formulation.

The translation of these technologies into the market and, therefore, in the development of new healing therapies, has several hurdles that should be addressed. From a biological perspective, the limited knowledge of the pathophysiology of patients is the major one. Both in the healthy and diseased states, there is a need to understand the in vivo fate of the interactions of nanoparticles with blood, tissue, cellular and intracellular compartments.
On the other side, from a technological point of view, the major obstacle is to gain insight into the physicochemical properties of such nanoscale systems as well as their in vivo behavior and toxicity.

For nanotechnology systems to have a feasible clinical scalability and market transfer potential, the difficulty in their development requires to be simplified. The goal is to fabricate reproducible, controlled and monitored nanotechnology platforms. Thus, there is a need to improve the synthesis and characterization of the nanotechnology-based wound healing systems as well as to introduce site-specificity and targeting ability to decrease the undesirable effects of these nanosystems in the human body. In addition, some aspects like systemic absorption or the polymers/materials used for their fabrication, that in general are no-FDA approved materials, need also to be addressed.

SUMMARY

Chronic wounds present a disrupted repair process, taking several months to show progress. They cause pain, infections, costs, and frequently lead to amputations or sepsis; persisting as a silent epidemic affecting over 40 million people worldwide. Traditional dressings cannot fully address all the wound healing necessities. Thus, new technologies are needed. A high variety of nanoplaforms are being explored for chronic wound treatment, specifically in the case of diabetic wounds. Herein, we focused on NPs, nanofibers and self-assembling nanocarriers used for the treatment of diabetic wounds. Among NPs, we can categorize them in two groups, active NPs and delivery systems. Metallic (AgNPs, AuNPs, etc) and ion release NPs have shown their potential as antimicrobial agents and enhancing the wound closure. On the other side, NPs for drug delivery have been applied for the sustained release of GFs, drugs or nucleic acids; and can be made from different polymers like polyesters, lipids, polysaccharides or peptides. In general, these systems are included in other formulations (gels, nanofibers) to ease its application. Nanofibers are ideal wound dressings as they can mimic the ECM of the skin and allow the oxygen/nutrients interchange. Moreover, they can load biomolecules in their matrix or even NPs encapsulating biomolecules to render different release profiles of the biomolecules that can match the needs of the wound physiopathology. Polymers like...
hyaluronic acid, collagen, SF, polyesters or self-assembled peptides have proved their potential for the fabrication of nanofiber as wound dressing. Liposomes are also interesting approaches for the treatment of wounds, especially for nucleic acids, as they can protect them from degradation and deliver them intracellularly, working as gene delivery systems. Nevertheless, more efforts are required for the obtaining of new nanomaterials that can be used and approved by the regulatory agencies.
TAKE HOME MESSAGES

- Traditional dressings cannot fully address all the chronic wound healing necessities, and new technologies are needed.
- Current new nanoplatforms used for chronic wounds healing includes nanoparticles, nanofibers and self-assembling nanocarriers.
- Metallic and ion release NPs have shown their potential as antimicrobial agents and improving wound closure. NPs can also be used as delivery systems for therapeutics like GFs, drugs or nucleic acids.
- Nanofibers are ideal wound dressings as they can mimic the skin ECM and allow the oxygen/nutrients interchange. Moreover, they can load biomolecules in their matrix or even nanocarriers encapsulating the active ingredients.
- Liposomes have a high potential for the intracellular delivery of genes involved in wound healing.
- Bigger efforts are needed to develop new nanomaterials that can be approved by the regulatory agencies. Safety assessment, differences in bioavailability, scale-up problems, among others, are some of the issues that need to be addressed.
ACKNOWLEDGMENTS AND FUNDING SOURCES

This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO/FEDER) through the project MAT2012-38793 and MAT2015-68906-R, and the Dermoglass project funded by CaixaImpulse Programme of Obra Social La Caixa (CaixaImpulse CI0015). Barbara Blanco-Fernandez acknowledges the Marie Skłodowska-Curie grant (agreement no. 712754) and the Severo Ochoa grant (SEV-2014-0425). O. Castano acknowledges the support from the Serra Hunter programme.

AUTHOR DISCLOSURE AND GHOSTWRITING

No competing financial interests exist. The content of this article was expressly written by the authors listed. No ghostwriters were used to write this article.
ABOUT THE AUTHORS

Barbara Blanco-Fernandez is postdoc (Marie Skłodowska-Curie fellow) in the group of Biomaterials for Regenerative therapies at the IBEC. She holds a Ph.D. in Pharmaceutical Science from the University of Santiago de Compostela. Previously, she joined as a postdoctoral research associate to the Molecular and Cellular Imaging Laboratory at Michigan State University. She worked as a nanotechnology scientist for skin delivery at the Pharmaceutical Company Reig Jofre.

Oscar Castaño is a Serra Hunter Fellow at the Electronics and Biomedical Engineering, Universitat de Barcelona. Miguel Ángel Mateos-Timoneda is a Senior Researcher affiliated at the CIBER-BBN in the group Biomaterials for Regenerative Therapies (IBEC). Elisabeth Engel is the Group Leader of the Biomaterials for Regenerative Therapies group at IBEC, and full professor in the Technical University of Catalonia (UPC). Soledad Perez-Amodio is a Senior Researcher affiliated at the CIBER-BBN in the group of Biomaterials for Regenerative Therapies (IBEC). She is also an associate professor in the UPC. She holds a Ph.D. in Cellular and Molecular Biology from the University of Amsterdam. She worked as a postdoctoral researcher at the Tissue Regeneration Group (University of Enschede), Plastic and Reconstructive Surgery (Erasmus Medical Centre, Rotterdam) and the department of Oral Cell Biology (Vrij University).
ABBREVIATIONS AND ACRONYMS

AgNPs = Silver nanoparticles
AuNPs = Gold Nanoparticles
bFGF = basic fibroblast growth factor
BG = Bioactive glass
CEC = chain entanglement concentration
CeONPs = cerium oxide nanoparticles
DFUs = diabetic foot ulcers
DOTAP = 1,2-dioleoyl-3-trimethylammonium-propane
ECM = Extracellular matrix
EGF = Epidermal growth factor
FDA = Food and Drug Administration
FGF = Fibroblast Growth Factor
GF = Growth factor
GM3S = ganglioside-monosialic acid 3 synthase
HIF-1a = Hypoxia-inducible factor 1-alpha
HPMC = hydroxypropyl methylcellulose
IGF-1 = insulin-like growth factor-1
KGF = Keratinocyte Growth Factor
MMP-9 = matrix metalloproteinases-9
mRNA = messenger RNAs
miRNA = microRNAs
MOFs = Metal−organic frameworks
MSC = Mesenchymal stem cells
MW = molecular weight
NHPUs = Non-healing pressure ulcers
NPs = Nanoparticles
PCL = polycaprolactone
PDGF = Platelet derived growth factor
PLA = poly(lactide)
PLGA = poly(lactide-co-glycolide)
PVA = poly(vinyl alcohol)
PEG = polyethylene glycol
PEO = polyethylene oxide
PU = polyurethane
ROS = reactive oxygen species
SDF-1 = Stromal cell-derived factor-1
SF = silk fibroin
Si = silicon
TNFα = tumor necrosis factor alpha
VUs = Venous ulcers
ZnO = Zinc oxide
3D = three-dimensional
REFERENCES


Figure 1. Schematic representation of nanocarriers used for chronic wound healing: self-assembled nanocarriers (liposomes, micelles, nanogels), nanoparticles (polymeric, inorganic, lipid) and nanofibers (plain, and encapsulating nanocarriers or therapeutic agents).
Figure 2. Antibacterial mechanism of action of metallic nanoparticles. Metal NPs provoke protein denaturalization, enzyme inactivation, DNA damage and the disassembly of ribosomes, as well as ROS generation. Altogether, promote the programmed bacterial cell death.
Figure 3. The topical administration of AuNPs conjugated to spherical nucleic acid for ganglioside-monomial acid 3 synthase (GM3S) shows a reduction in local GM3S expression and heals the wound in 12 days in diabetic mice wounds. An increase in granulation tissue, new blood vessels formation, and IGF1 and EGF receptor phosphorylation is observed. (A) SNA are 13-nm gold cores functionalized with thiolated siRNA duplexes (targeted to) and oligoethylene glycol for colloidal stability. (B-E) Topical application of GM3S SNA prevents the delayed wound healing in the DIO mouse. (B) Representative clinical images of wounds. (C) Computerized measurements of the open wound area. (D) Epidermal gap (the maximum distance between KCs at the leading wound edges) was measured by computerized morphometry. (E) Representative histologic images of NT and NS SNA- and GM3S SNA-treated wounds at day 12. D, dermis; E, epidermis; EG, epidermal gap; GT, granulation tissue. (Scale bar: 500 μm.) (E) Granulation tissue area and vascularity (CD31+ staining) of the diabetic wounds. Adapted from 48 with permission.
Figure 4. Nanoparticles of fusion protein of elastin-like peptides (ELP) and keratinocyte growth factor (KGF) enhances wound healing in diabetic mice by promoting re-epithelization and granulation tissue formation. (A-B) TEM images of KGF–ELP (A) and ELP (B) NPs; scale bar = 100 nm. (C) Quantification of granulation tissue formation in diabetic mice wounds, after the treatment with a fibrin gel, KGF-fibrin gel, ELP-NPs in fibrin gel, ELP-KGF-NPs in fibrin gel and KGF and ELP-NPs in fibrin gel for 14 days. (D-I) Re-epithelization enhancement of wounds of diabetic mice after treatment. Hematoxylin-eosin staining of wounds after 14 days of treatment with fibrin gel (D), KGF-fibrin gel (E), ELP-NPs in fibrin gel (F), ELP-KGF-NPs in fibrin gel (G) and KGF and ELP-NPs in fibrin gel (H). Dotted line represents the re-epithelialization tissue (scale bar of 400 μm). (F) Re-epithelialization quantification, normalized to the initial wound gap. Adapted from 78 with permission.
Figure 5. Silk fibroin nanofibers meshes coated with spider silk fusion proteins FN-4RC (contains motifs of fibronectin for cell adhesion) and/or Lac-4RC (contains lactoferrin, an antimicrobial peptide). When both fusion proteins are used, a faster wound healing in a diabetic model is observed, provoked by a better granulation tissue formation and re-epithelialization compared to a positive control. (A) Scheme representing the fabrication and morphology of the dressing. (B-C) Wound evolution after no treatment (UNT) and treatment with Duoderm wound dressing (positive control, DD), uncoated mat (AaSF), mat coated with FN-4RC (AaSF-FN), mat coated with Lac-4RC (AaSF-Lac) and mat coated with both (AaSF-FN-Lac). Scale bar 100mm. Adapted from 100 with permission.
Figure 6. A skin-inspired 3D bilayer scaffold made of gelatin, AgNPs and PDGF-BB had a faster wound healing, more collagen deposition, blood vessels formation and re-epithelization in diabetic wounds. (A) Representation of the preparation process of silver and PDGF-BB co-loaded bilayer 3D scaffolds. (B-D) Histological observations of skin wound healing treated with scaffold, silver-loaded scaffold, PDGF-BB-loaded scaffold and silver and PDGF-BB co-loaded scaffold (B) Masson trichrome staining shows collagen deposition and new blood vessel formation of treated wounds. (C) Quantification of new blood vessels. (D) Hematoxylin-eosin staining showing the re-epithelialization of the treated wounds. Adapted from 103 with permission.
Figure 7. Nanofibers meshes made of Collagen I and PCL with different fiber organizations have different outputs in wound healing. Crossed nanofibers, which mimics the collagen pattern in skin, have a better wound healing rate and promotes angiogenesis in diabetic rats. (A) Scanning Electron Microscopy images of the nanofibers with different organizations (random, aligned and crossed). (B-C) Wound evolution in diabetic rats after treatment with the scaffolds. (D) Quantification of von Willebrand factor-positive vessels. Adapted from 105 with permission.
Figure 8. Cationic liposomes made of an electrostatic complex between the plasmid of human recombinant PDGF-B, integrin receptor selective RGDK-lipopeptide and cholesterol are able to improve wound healing in diabetic rats. The administration of RGDK-lipopeptide 1:rhPDGF-B on wound od diabetic animals show a faster wound healing rate, re-epithelialization and fibrocollagen, keratin and vessels formation. (A) Relative wound healing and (B) wound images before the administration of the treatment (B.A-C) and after 10 days of treatment (B.D-F) with RGDK-lipopeptide 1:rhPDGF-B complex (B.D), RGDK-liposome (B.E) and RGEK-lipopeptide 2:rhPDGF-B complex (B.F) in diabetic rats after the subcutaneous administration of a single dose. (C) Hematoxylin-eosin (C.A-D) and masson’s trichrome (C.E-H) tissue staining of wounds before the treatment (C.A and C.E) and 10 days after the treatment with RGDK-lipopeptide 1:rhPDGF-B (C.B and F); liposomes of RGDK-lipopeptide 1 (C.C and G) and RGEK-lipopeptide 2:rhPDGF-B (C.D and H). Adapted from 129 with permission.
<table>
<thead>
<tr>
<th>FORMULATION</th>
<th>ANIMAL MODEL</th>
<th>AREA (CM²)</th>
<th>TIME* (DAYS)</th>
<th>REFERENCES</th>
</tr>
</thead>
<tbody>
<tr>
<td>In a chitosan-PEG hydrogel</td>
<td>Rabbit + Diabetes 1</td>
<td>4</td>
<td>8</td>
<td>40</td>
</tr>
<tr>
<td>Bilayer of AgNPs-loaded gelatine cryogel and PDGF-BB gelatine scaffold</td>
<td>Mice + Diabetes 2 (C57BL/6JNju DIO)</td>
<td>0.5</td>
<td>9</td>
<td>110</td>
</tr>
<tr>
<td>In a chitosan/dextran hydrogel</td>
<td>Mice + Diabetes 1</td>
<td>1.8</td>
<td>10</td>
<td>43</td>
</tr>
<tr>
<td>With nicotinamice and impregnated in nonwoven viscose fabrics</td>
<td>Mice + burn + Diabetes 1</td>
<td>4</td>
<td>10</td>
<td>148</td>
</tr>
<tr>
<td>In a chitosan/starch gel</td>
<td>Rat + Diabetes 1</td>
<td>0.8</td>
<td>12</td>
<td>149</td>
</tr>
<tr>
<td>In a hyaluronic gel</td>
<td>Rat + old + Diabetes 1</td>
<td>2</td>
<td>14</td>
<td>100</td>
</tr>
<tr>
<td>In a poly(sulfo betaine acrylamide) hydrogel</td>
<td>Rat + infected + Diabetes 1</td>
<td>1.8</td>
<td>15</td>
<td>150</td>
</tr>
<tr>
<td>With an insulin coat</td>
<td>Rat + Diabetes 1</td>
<td>1.8</td>
<td>15</td>
<td>151</td>
</tr>
<tr>
<td>e-polysine</td>
<td>Rat + infected + Diabetes 1</td>
<td>1.8</td>
<td>18</td>
<td>152</td>
</tr>
<tr>
<td>In poly(acrylic acid) nanogels</td>
<td>Mice + Diabetes 2 (db/db)</td>
<td>-</td>
<td>18</td>
<td>41</td>
</tr>
<tr>
<td>In cellulose nanocrystals</td>
<td>Mice + Diabetes 1</td>
<td>0.5</td>
<td>18</td>
<td>45, 46</td>
</tr>
<tr>
<td>Technology</td>
<td>Animals</td>
<td>Treatment</td>
<td>Time 1</td>
<td>Time 2</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>---------</td>
<td>-----------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>In polydopamine hydrogels decorated with polyaniline and PVA</td>
<td>Rat + infected+ Diabetes 1</td>
<td>0.2</td>
<td>20</td>
<td>44</td>
</tr>
<tr>
<td>With recombinant human EGF in PU foams</td>
<td>Mice + Diabetes 1</td>
<td>0.3</td>
<td>20</td>
<td>42</td>
</tr>
<tr>
<td>In polyelectrolyte multilayers of poly(allylaminehydrochloride) and poly(acrylic acid)</td>
<td>Mice + splints Diabetes 2 (db/db)</td>
<td>0.3</td>
<td>21</td>
<td>153</td>
</tr>
<tr>
<td>Stabilized with bacteria supernatant</td>
<td>Mice + infected + Diabetes 1</td>
<td>4</td>
<td>14-28</td>
<td>154, 155</td>
</tr>
<tr>
<td>With epigallocatechin gallate dispersed in N₂ topically administered</td>
<td>Mice + Diabetes 1</td>
<td>1cm excision</td>
<td>7</td>
<td>156</td>
</tr>
<tr>
<td>With receptor for advanced glycation end-products, epigallocatechin gallate and α-lipoic acid</td>
<td>Mice + Diabetes 1</td>
<td>1cm excision</td>
<td>7</td>
<td>52</td>
</tr>
<tr>
<td>AuNP With antimicrobial peptide LL37 and VEGF plasmid</td>
<td>Mice + infected+ Diabetes 1</td>
<td>0.1</td>
<td>10</td>
<td>33</td>
</tr>
<tr>
<td>With spherical nucleic acid of ganglioside-monosialic acid 3 synthase dispersed in Aquaphor</td>
<td>Mice + splinted+ Diabetes 2 (T2D)</td>
<td>0.3</td>
<td>12</td>
<td>55</td>
</tr>
<tr>
<td>With calreticulin and chitosan</td>
<td>Mice +</td>
<td>0.3</td>
<td>16</td>
<td>53</td>
</tr>
<tr>
<td>SI</td>
<td>BG</td>
<td>NPs</td>
<td>Cerium oxide</td>
<td>CuNPs</td>
</tr>
<tr>
<td>----</td>
<td>----</td>
<td>-----</td>
<td>--------------</td>
<td>-------</td>
</tr>
<tr>
<td>0.5</td>
<td>Diabetes 1 (db/db) Mice</td>
<td>Vaseline</td>
<td>In a poly(PHBV) membrane</td>
<td>With miR-146a</td>
</tr>
<tr>
<td>13</td>
<td>Diabetes 1 (db/db) Mice</td>
<td>Rat + Diabetes 1 Mice</td>
<td>Rat + Diabetes 2 (db/di)</td>
<td>Mice + Diabetes 2 (db/di)</td>
</tr>
<tr>
<td>74</td>
<td>BG</td>
<td>Cerium oxide NPs</td>
<td>With miR-146a</td>
<td>Modified with folic acid in an organic framework dispersed in a polydiolcitrate hydrogel</td>
</tr>
<tr>
<td>73</td>
<td>Diabetes 1 (db/db) Mice</td>
<td>Rat + Diabetes 1 Mice</td>
<td>Rat + Diabetes 2 (db/di)</td>
<td>Mice + Diabetes 2 (db/di)</td>
</tr>
</tbody>
</table>

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
<table>
<thead>
<tr>
<th>NO</th>
<th>PLGA NPS WITH POLYETHYLEMININE/DIAZENIUMDIOLATE</th>
<th>MICE + INFECTION+ DIABETES1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chitosan/PEG hydrogel</td>
<td>Mice + Diabetes1</td>
<td>0.12 0.5 77 14 76 62</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NP compositon</td>
<td>Formulation</td>
<td>Biomolecule</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>PLGA</td>
<td>In (poly(vinyl alcohol)-borate) hydrogel</td>
<td>Insulin</td>
</tr>
<tr>
<td></td>
<td>In poly(ether)urethane–polydimethylsiloxane/fibrin-based scaffolds</td>
<td>VEGF and bFGF</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>VEGF</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>EGF</td>
</tr>
<tr>
<td></td>
<td>In Carbopol 980</td>
<td>Ferulic Acid (FA)</td>
</tr>
<tr>
<td>Lipid</td>
<td>-</td>
<td>TNFα</td>
</tr>
<tr>
<td>Lecithin</td>
<td>In Pluronic gel</td>
<td>Deferoxamine</td>
</tr>
<tr>
<td>Protamine</td>
<td>In calcium alginate hydrogel/hyaluronan</td>
<td>-</td>
</tr>
<tr>
<td>Oligosaccharides</td>
<td>Delivery System</td>
<td>Growth Factor</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
<td>---------------</td>
</tr>
<tr>
<td>ELP</td>
<td>In Fibrin gel</td>
<td>KGF</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In Fibrin gel</td>
<td>SDF-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In Fibrin gel</td>
<td>SDF-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chitosan</td>
<td>Collagen/Alginate</td>
<td>Curcumin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compositio n</td>
<td>Biomolecule</td>
<td>Animal model</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Chitosan + PVA</td>
<td>Desferrioxamine</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ZnO</td>
<td>Rabbit + diabetes 1</td>
</tr>
<tr>
<td>Hyaluronic acid</td>
<td>AgNPs</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td>Hyaluronic acid+ collagen</td>
<td>VEGF, PDGF and EGF&amp;bFGF-loaded gelatin NPs</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td>HPMC+PEO</td>
<td>Beta glucan</td>
<td>Mice + diabetes 2 (BKS db)</td>
</tr>
<tr>
<td>SF</td>
<td>-</td>
<td>Rabbit + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>Insulin loaded MPs</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>EGF and ciprofloxacin</td>
<td>Rabbit + Diabetes 1</td>
</tr>
<tr>
<td></td>
<td>Adipose MSC or decellularized</td>
<td>Mice + diabetes 2 (db/db)</td>
</tr>
<tr>
<td>SF +PLGA</td>
<td>-</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td>SF +PVA</td>
<td>hrEGF</td>
<td>rabbit + diabetes 1</td>
</tr>
<tr>
<td>Collagen +PLGA</td>
<td>rhPDGF</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>glucophage</td>
<td></td>
</tr>
<tr>
<td>Collagen+PCCL</td>
<td>Dimethyloxalyl-glycine</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BGs NPs</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td>Gelatin</td>
<td>silicate-based bioceramics</td>
<td>Mice + diabetes 1</td>
</tr>
<tr>
<td>PLA</td>
<td>Dimethyloxalylglycine-loaded MSNPs</td>
<td>Mice + diabetes 1</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>PCL</td>
<td>curcumin</td>
<td>Mice + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>Aloe vera + MSC</td>
<td>Mice + diabetes 2</td>
</tr>
<tr>
<td></td>
<td>Bixin</td>
<td>Mice + diabetes 1</td>
</tr>
<tr>
<td>PCL+PEG</td>
<td>EGF + bFGF</td>
<td>Mice + burn +diabetes 1</td>
</tr>
<tr>
<td>PCL+ Gum tragacanth</td>
<td>Curcumin + MSC</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>Aloe vera+ rhEGF</td>
<td>Mice + splinted + diabetes 2 (db/db)</td>
</tr>
<tr>
<td>PLGA</td>
<td>rhPDGF</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>Neurotensin + cellulose nanocrystals</td>
<td>Mice + diabetes 2</td>
</tr>
<tr>
<td></td>
<td>Metformina</td>
<td>Rat + diabetes 1</td>
</tr>
<tr>
<td></td>
<td>PVA + Curdlan</td>
<td>Silver nitrate</td>
</tr>
<tr>
<td></td>
<td>PLA-PEG</td>
<td>bFGF</td>
</tr>
<tr>
<td>RAD</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Heparin-mimic amphiphilic peptides</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Multidomain peptide</td>
<td>-</td>
</tr>
<tr>
<td>Composition</td>
<td>Biomolecule</td>
<td>Animal model</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>---------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>DOTAP + Sodium cholate</td>
<td>Keap1 siRNA</td>
<td>Mice + stent + diabetes 2 (db/db)</td>
</tr>
<tr>
<td>Unknown</td>
<td>microRNA</td>
<td>Mice + diabetes 2 (db/db)</td>
</tr>
<tr>
<td>RGDK-lipopeptide + cholesterol</td>
<td>miR-132</td>
<td>PDGF-B gen Rat + diabetes 1 (STZ)</td>
</tr>
<tr>
<td>Phosphatidylcholine + cholesterol + tween80 + stearylamine</td>
<td>Bacteriophages</td>
<td>Mice + infected+ diabetes 1</td>
</tr>
<tr>
<td>Phosphatidylcholine + DOTAP + ATP</td>
<td>ATP</td>
<td>Rabbit + ischemic + diabetes 1</td>
</tr>
<tr>
<td>Hyaluronic acid + cholesterol + DOTAP + hydrogenated phosphatidylcholine</td>
<td>EGF, IGF-1, PDGF-A</td>
<td>Mice + diabetes 1</td>
</tr>
<tr>
<td>Phosphatidylcholine + cholesterol + Phosphatidate + Phosphoethanolamine- n-(lissamine rhodamine b sulfonyl)</td>
<td>SDF-1</td>
<td>Mice + diabetes 2</td>
</tr>
<tr>
<td>Phosphocholine + Phosphoethanolamine + cholesterol + sphingomyelin</td>
<td>syndecan-4, PDGF -BB</td>
<td>Mice + stent+ diabetes 2 (ob/ob)</td>
</tr>
</tbody>
</table>